<![CDATA[HIStalk Sponsor Announcements

<![CDATA[HIStalk Sponsor Announcements - Announcements]]> https://histalk.com/forum/ Fri, 29 May 2026 15:02:23 +0000 MyBB <![CDATA[MEDITECH customers rank among the nation's top critical access hospitals]]> https://histalk.com/forum/showthread.php?tid=2305 Wed, 27 May 2026 14:49:18 +0000 RMcCarthy]]> https://histalk.com/forum/showthread.php?tid=2305 MEDITECH celebrates the achievements of small, rural facilities during National Hospital Week

Some of our most vital hospitals are those small, rural facilities that provide 24/7 emergency care and acute services to remote, often underserved communities. Becker’s Hospital Review recently released a list of the top 100 Critical Access Hospitals (CAHs) to know in 2026, which includes over 20 MEDITECH customers. Read more here.]]> MEDITECH celebrates the achievements of small, rural facilities during National Hospital Week

Some of our most vital hospitals are those small, rural facilities that provide 24/7 emergency care and acute services to remote, often underserved communities. Becker’s Hospital Review recently released a list of the top 100 Critical Access Hospitals (CAHs) to know in 2026, which includes over 20 MEDITECH customers. Read more here.]]> <![CDATA[Linus Health Digital Cognitive Assessments Meet or Surpass New CEOi Benchmarks]]> https://histalk.com/forum/showthread.php?tid=2304 Wed, 27 May 2026 14:37:09 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2304 Linus Health Digital Cognitive Assessments Meet or Surpass New CEOi Benchmarks for Early Cognitive Impairment Detection

Published and emerging evidence shows strong alignment across detection, diagnostic support, and cognitive profiling—while supporting faster, more actionable brain health workflows

BOSTON, May 27, 2026 -- Linus Health, an AI-driven brain health company focused on early detection and proactive intervention, announced that its digital solutions meet or exceed the performance criteria suggested in recent recommendations from the Global CEO Initiative on Alzheimer's Disease (CEOi) for clinic-based digital cognitive assessments.

Published in Alzheimer's & Dementia, the CEOi framework defines three core clinical use cases for supervised, in-clinic digital cognitive assessments (DCAs):

Initial detection of cognitive impairment (Detection DCA);
Diagnostic support for mild cognitive impairment (MCI) and dementia (Diagnostic DCA); and
Cognitive profile characterization to aid in subtyping or etiologic workup (Profile Characterization Aid DCA).

The workgroup calls for digital tools to at least match, and ideally improve upon, a set of ambitious performance measures, while fitting real-world clinical workflows.

Direct comparison to the CEOi detection benchmark

Within the CEOi Detection DCA benchmarks—approximately 3 to 5 minutes, 80% sensitivity, and 85% specificity—Linus Health's remote-enabled Digital Assessment of Cognition (DAC) exceeded the suggested benchmark in an independent test set, achieving 90.7% sensitivity and 100% specificity for distinguishing cognitively unimpaired individuals from those with cognitive impairment, including MCI and dementia.

The DCR, a <3-minute assessment, achieves strong performance in brief cognitive evaluations, with 80% sensitivity and 73% specificity for general cognitive impairment and 81% sensitivity and 80% specificity for verbal memory impairment. DCR studies showed higher sensitivity and overall accuracy compared with MMSE, Mini-Cog, and MoCA (based on research planned for presentation at the Alzheimer's Association International Conference [AAIC] 2026), directly supporting the CEOi recommendation that brief DCAs match or outperform legacy non-digital screening tools.

Strong alignment in diagnostic-aid workflows

Within the CEOi Diagnostic Aid DCA benchmarks—approximately 10 to 20 minutes, 85% sensitivity and 90% specificity for MCI detection—Linus Health's DAC achieved 82.9% sensitivity and 100% specificity for distinguishing cognitively unimpaired individuals from those with MCI, with a positive predictive value of 100% and negative predictive value of 78% in the study sample. The same DAC research showed 73.7% sensitivity and 85.7% specificity for distinguishing MCI from dementia. These data show that Linus Health meets the CEOi specificity benchmark for diagnostic support and approaches the suggested sensitivity threshold, while delivering DAC in about seven minutes—shorter than the CEOi's suggested 10- to 20-minute diagnostic aid window.

Evidence also supports profile characterization and etiologic workup

For the CEOi Profile Characterization Aid DCA use case, the guidelines describe a more comprehensive tool intended to support etiologic workup and uses 85% sensitivity and 90% specificity as an example benchmark for detecting MCI due to Alzheimer's disease. Linus Health is one of the only DCAs tackling this critical third use case. Linus' evidence base supports that goal in two ways:

DAC demonstrates the ability to differentiate clinically meaningful phenotypes, including amnestic, dysexecutive, and multi-domain MCI subtypes; has greater than 90% concordance with classifications derived from 2- to 3-hour comprehensive neuropsychological evaluations; and achieved (page 290) a 93% negative predictive value for ruling out p-tau217 positivity in real-world settings.
DCR predicts amyloid PET positivity with an AUC of 0.81. In a separate DCR analysis focused on identifying patients with MCI or mild dementia likely due to Alzheimer's disease, a combination of DCR's cognitive-impairment and amyloid-prediction models achieved (page 289) 83% sensitivity and 85% specificity for identifying that cohort.

These findings support the CEOi framework's emphasis on understanding not only whether cognitive impairment is present, but also what pattern of impairment is emerging and whether Alzheimer's pathology may be more likely.

"Clear, clinically relevant standards are essential for moving digital cognitive assessment from promise to routine practice," said David Bates, PhD, CEO and co-founder of Linus Health. "The CEOi's recommendations reinforce the direction we have believed in from the beginning: brief, scalable, scientifically grounded tools that deliver more actionable information than legacy screening approaches and help patients get to the right next step sooner. Merely identifying patients with dementia is insufficient for the future of brain health. Patients deserve more."

Together, these results support the use of Linus Health solutions as rapid, low-burden tools that provide primary care physicians with what they need to determine which patients require deeper workup, specialist referral, or longitudinal monitoring.

"Digital cognitive assessments should do far more than recreate paper tests on a screen," said Alvaro Pascual-Leone, MD, PhD, co-founder and chief medical officer of Linus Health. "They should capture richer behavioral signals, help clinicians interpret what those signals mean, and support better decisions about who needs follow-up, which patients may be at highest risk, and how care can be tailored earlier in the disease course."

By separating standards for detection, diagnostic support, and profile characterization, the CEOi recommendations provide health systems, clinicians, researchers, and developers with a more practical framework for evaluating clinical utility. Linus Health believes the recommendations will help accelerate broader adoption of more sensitive, scalable, and clinically meaningful brain health tools—and underscore the company's continued focus on evidence-based solutions that improve earlier identification and intervention.

About Linus Health
Linus Health is a Boston-based digital health company focused on improving brain health around the world. The company develops science-driven digital assessments and AI-enabled analytics that help clinicians and researchers identify cognitive change earlier, guide next steps in care, and support more proactive, personalized intervention. Linus Health works with healthcare delivery organizations, research institutions, and life sciences partners to advance earlier detection and better brain health outcomes.

Media Contact
Supreme Communications for Linus Health
linushealthPR@supremecomms.ai]]> Linus Health Digital Cognitive Assessments Meet or Surpass New CEOi Benchmarks for Early Cognitive Impairment Detection

Published and emerging evidence shows strong alignment across detection, diagnostic support, and cognitive profiling—while supporting faster, more actionable brain health workflows

Initial detection of cognitive impairment (Detection DCA);
Diagnostic support for mild cognitive impairment (MCI) and dementia (Diagnostic DCA); and
Cognitive profile characterization to aid in subtyping or etiologic workup (Profile Characterization Aid DCA).

DAC demonstrates the ability to differentiate clinically meaningful phenotypes, including amnestic, dysexecutive, and multi-domain MCI subtypes; has greater than 90% concordance with classifications derived from 2- to 3-hour comprehensive neuropsychological evaluations; and achieved (page 290) a 93% negative predictive value for ruling out p-tau217 positivity in real-world settings.
DCR predicts amyloid PET positivity with an AUC of 0.81. In a separate DCR analysis focused on identifying patients with MCI or mild dementia likely due to Alzheimer's disease, a combination of DCR's cognitive-impairment and amyloid-prediction models achieved (page 289) 83% sensitivity and 85% specificity for identifying that cohort.

These findings support the CEOi framework's emphasis on understanding not only whether cognitive impairment is present, but also what pattern of impairment is emerging and whether Alzheimer's pathology may be more likely.

"Clear, clinically relevant standards are essential for moving digital cognitive assessment from promise to routine practice," said David Bates, PhD, CEO and co-founder of Linus Health. "The CEOi's recommendations reinforce the direction we have believed in from the beginning: brief, scalable, scientifically grounded tools that deliver more actionable information than legacy screening approaches and help patients get to the right next step sooner. Merely identifying patients with dementia is insufficient for the future of brain health. Patients deserve more."

Together, these results support the use of Linus Health solutions as rapid, low-burden tools that provide primary care physicians with what they need to determine which patients require deeper workup, specialist referral, or longitudinal monitoring.

"Digital cognitive assessments should do far more than recreate paper tests on a screen," said Alvaro Pascual-Leone, MD, PhD, co-founder and chief medical officer of Linus Health. "They should capture richer behavioral signals, help clinicians interpret what those signals mean, and support better decisions about who needs follow-up, which patients may be at highest risk, and how care can be tailored earlier in the disease course."

By separating standards for detection, diagnostic support, and profile characterization, the CEOi recommendations provide health systems, clinicians, researchers, and developers with a more practical framework for evaluating clinical utility. Linus Health believes the recommendations will help accelerate broader adoption of more sensitive, scalable, and clinically meaningful brain health tools—and underscore the company's continued focus on evidence-based solutions that improve earlier identification and intervention.

About Linus Health
Linus Health is a Boston-based digital health company focused on improving brain health around the world. The company develops science-driven digital assessments and AI-enabled analytics that help clinicians and researchers identify cognitive change earlier, guide next steps in care, and support more proactive, personalized intervention. Linus Health works with healthcare delivery organizations, research institutions, and life sciences partners to advance earlier detection and better brain health outcomes.

Media Contact
Supreme Communications for Linus Health
linushealthPR@supremecomms.ai]]> <![CDATA[The State of Healthcare Contact Centers: What the Data Says (Webinar May 28)]]> https://histalk.com/forum/showthread.php?tid=2303 Thu, 21 May 2026 23:28:57 +0000 MKothe]]> https://histalk.com/forum/showthread.php?tid=2303 register here.

A sneak peek at some of the data:

84% of respondents said tech gaps affect their ability to hire and keep operators
46% cite integration complexity as the #1 barrier to adopting new technology
87% rate themselves as beginning or intermediate in AI maturity
Only 40% have EHR integration — despite averaging 5+ tools in their stack

More Details
A lot of healthcare operator environments look fine on paper. Calls are getting answered. Teams are keeping things moving. And from a distance, it can look like the operation is holding up.

But that’s often where the real problem starts, because “answered quickly” is not the same as “handled well.” A call can be picked up fast and still turn into a long hold, another transfer, another system switch, another attempt to find the right person — and another frustrating experience for the patient or referring provider on the other end.

PerfectServe surveyed 100+ healthcare IT and operations leaders about the state of hospital operator environments, from switchboards and transfer workflows to the broader call management technology stack behind them. The data is clear: many organizations are measuring the wrong things, operating with more fragmented stacks than they realize, and asking operators to work around systems that were never built for the complexity they handle today.

This live session brings together contact center consultants and a product specialist who works inside these environments every day to unpack what the data means and what health systems can do about it.

What You’ll Take Away
Every topic in this session is tied to a decision you may need to make or a conversation you may need to have internally.

Benchmark data to see how your operator environment compares to peers across the industry.
A clearer picture on UCaaS vs. CCaaS — and where switchboard technology fits in.
Real talk on AI, tech adoption, and where hospital operator environments are heading in the next 12–18 months.
Walk away with a framework for taking this data back to your leadership team, along with the language to build the internal case for change.

Who Should Attend?
Built for IT and operations leaders responsible for how care teams connect, communicate, and coordinate inside the health system.

Patient Access & Transfer Center Leaders – You’ll recognize the performance gaps the data describes and leave with language to build the internal case for change.
IT & Unified Communications Leaders – You’ll get an honest assessment of where integration complexity is stalling progress and what a more consolidated architecture looks like in practice.
Contact Center Operations Leaders – You’ll see your workforce and workflow challenges reflected in the data and hear directly from peers who have navigated them.

]]> register here.

A sneak peek at some of the data:

84% of respondents said tech gaps affect their ability to hire and keep operators
46% cite integration complexity as the #1 barrier to adopting new technology
87% rate themselves as beginning or intermediate in AI maturity
Only 40% have EHR integration — despite averaging 5+ tools in their stack

Benchmark data to see how your operator environment compares to peers across the industry.
A clearer picture on UCaaS vs. CCaaS — and where switchboard technology fits in.
Real talk on AI, tech adoption, and where hospital operator environments are heading in the next 12–18 months.
Walk away with a framework for taking this data back to your leadership team, along with the language to build the internal case for change.

Who Should Attend?
Built for IT and operations leaders responsible for how care teams connect, communicate, and coordinate inside the health system.

Patient Access & Transfer Center Leaders – You’ll recognize the performance gaps the data describes and leave with language to build the internal case for change.
IT & Unified Communications Leaders – You’ll get an honest assessment of where integration complexity is stalling progress and what a more consolidated architecture looks like in practice.
Contact Center Operations Leaders – You’ll see your workforce and workflow challenges reflected in the data and hear directly from peers who have navigated them.

]]> <![CDATA[AMIA Amplify Poster Session: FDB Improves Medication Guidance]]> https://histalk.com/forum/showthread.php?tid=2302 Thu, 21 May 2026 13:39:31 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2302 AMIA Amplify Poster Session: FDB Pharmacists Show Patient-Specific Medication Guidance Can Reduce Pharmacy Alerts by 70%

Research demonstrates that consolidating medication guidance around patient risk can reduce alert fatigue and help pharmacists focus more time on patient care.

SOUTH SAN FRANCISCO, Calif., May 15, 2026 -- Clinical informatics pharmacists from FDB (First Databank, Inc.), a leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will present research at the 2026 AMIA Amplify Informatics Conference demonstrating how a patient-specific approach to medication clinical decision support (CDS) reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting.

The findings highlight how consolidating multiple medication safety alerts into a single, actionable alert based on the patient's most clinically relevant risk can significantly reduce alert fatigue, streamline pharmacist workflows, and support more meaningful patient interactions.

Usha Desiraju, PharmD, manager of informatics and clinical content at FDB, and Michael T. Silver, PharmD, clinical informatics pharmacist at FDB, will present the poster, "Optimizing Community Pharmacy Workflows with Enhanced CDS Tools" (Poster 109), during Poster Session 2 from 5:00 p.m. to 6:30 p.m. on Wednesday, May 20.

Today's community pharmacists must review medication alerts independently across multiple clinical domains, including drug-drug interactions, duplicate therapy, dosing, drug-disease contraindications, and specialty population precautions. This fragmented approach can generate hundreds of alerts per shift, contributing to cognitive overload, burnout, and the risk that critical safety signals may be overlooked.

FDB's re-engineered approach consolidates medication screening across clinical domains and presents pharmacists with the most clinically pertinent risk for each patient, along with recommended next-best actions.

To evaluate the approach in practice, the FDB research team analyzed medication screening data from a large national community pharmacy. Each alert was mapped to a single primary clinical outcome, or "Clinical Consequence." Using a proprietary API, alerts associated with the same Clinical Consequence were aggregated into a unified "Risk of" message paired with recommended actions, such as contacting the prescriber, reaching out to the patient, or providing patient-specific counseling materials.

The approach also incorporated intelligent alert management features, including suppression of repeat alerts based on prior pharmacist overrides, expiration logic for ICD-10-CM codes tied to acute conditions, and escalation or downgrading of alerts based on patient-specific predisposing and mitigating factors.

"Community pharmacists are doing more than ever for their patients, yet the volume of alerts they face each day can work against the very safety those alerts are designed to support," said Desiraju. "This research shows that a consolidated, risk-based approach can re-engineer medication CDS around both the patient and the pharmacist workflow by surfacing the single most important risk — and the action that should follow — instead of asking pharmacists to piece together siloed warnings themselves."

Before implementation, pharmacists received an average of 241.5 alerts per 250 prescriptions. After implementation of the consolidated, risk-based approach, alert volume dropped to fewer than 50 alerts per 250 prescriptions — a 70% overall reduction.

Pharmacists' acceptance of recommended next-best actions exceeded 75%, and participants also reported higher satisfaction and more dedicated time for patient interaction.

"What stood out in the results is that reducing alert volume by this magnitude did not come at the expense of clinical rigor," said Silver. "It came from organizing clinical knowledge in a more meaningful and patient-specific way. When pharmacists trust that the alerts surfaced represent the highest priority risks for a particular patient, they can act more confidently and spend more time where it matters most — with the patient."

FDB delivers this next-generation approach to medication guidance through FDB Navigo™, a web-based API solution that replaces siloed, severity-based alerts with consolidated, risk-based guidance aligned with real-world clinical decision-making.

As community pharmacists continue to expand their responsibilities — including vaccinations, health screenings, and medication therapy management — reducing the cognitive burden associated with legacy alerting systems is becoming increasingly important. By standardizing responses across pharmacy locations and surfacing more actionable guidance, FDB Navigo helps support more consistent, efficient, and patient-centered care.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health, elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> AMIA Amplify Poster Session: FDB Pharmacists Show Patient-Specific Medication Guidance Can Reduce Pharmacy Alerts by 70%

Research demonstrates that consolidating medication guidance around patient risk can reduce alert fatigue and help pharmacists focus more time on patient care.

SOUTH SAN FRANCISCO, Calif., May 15, 2026 -- Clinical informatics pharmacists from FDB (First Databank, Inc.), a leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will present research at the 2026 AMIA Amplify Informatics Conference demonstrating how a patient-specific approach to medication clinical decision support (CDS) reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting.

The findings highlight how consolidating multiple medication safety alerts into a single, actionable alert based on the patient's most clinically relevant risk can significantly reduce alert fatigue, streamline pharmacist workflows, and support more meaningful patient interactions.

Usha Desiraju, PharmD, manager of informatics and clinical content at FDB, and Michael T. Silver, PharmD, clinical informatics pharmacist at FDB, will present the poster, "Optimizing Community Pharmacy Workflows with Enhanced CDS Tools" (Poster 109), during Poster Session 2 from 5:00 p.m. to 6:30 p.m. on Wednesday, May 20.

Today's community pharmacists must review medication alerts independently across multiple clinical domains, including drug-drug interactions, duplicate therapy, dosing, drug-disease contraindications, and specialty population precautions. This fragmented approach can generate hundreds of alerts per shift, contributing to cognitive overload, burnout, and the risk that critical safety signals may be overlooked.

FDB's re-engineered approach consolidates medication screening across clinical domains and presents pharmacists with the most clinically pertinent risk for each patient, along with recommended next-best actions.

To evaluate the approach in practice, the FDB research team analyzed medication screening data from a large national community pharmacy. Each alert was mapped to a single primary clinical outcome, or "Clinical Consequence." Using a proprietary API, alerts associated with the same Clinical Consequence were aggregated into a unified "Risk of" message paired with recommended actions, such as contacting the prescriber, reaching out to the patient, or providing patient-specific counseling materials.

The approach also incorporated intelligent alert management features, including suppression of repeat alerts based on prior pharmacist overrides, expiration logic for ICD-10-CM codes tied to acute conditions, and escalation or downgrading of alerts based on patient-specific predisposing and mitigating factors.

"Community pharmacists are doing more than ever for their patients, yet the volume of alerts they face each day can work against the very safety those alerts are designed to support," said Desiraju. "This research shows that a consolidated, risk-based approach can re-engineer medication CDS around both the patient and the pharmacist workflow by surfacing the single most important risk — and the action that should follow — instead of asking pharmacists to piece together siloed warnings themselves."

Before implementation, pharmacists received an average of 241.5 alerts per 250 prescriptions. After implementation of the consolidated, risk-based approach, alert volume dropped to fewer than 50 alerts per 250 prescriptions — a 70% overall reduction.

Pharmacists' acceptance of recommended next-best actions exceeded 75%, and participants also reported higher satisfaction and more dedicated time for patient interaction.

"What stood out in the results is that reducing alert volume by this magnitude did not come at the expense of clinical rigor," said Silver. "It came from organizing clinical knowledge in a more meaningful and patient-specific way. When pharmacists trust that the alerts surfaced represent the highest priority risks for a particular patient, they can act more confidently and spend more time where it matters most — with the patient."

FDB delivers this next-generation approach to medication guidance through FDB Navigo™, a web-based API solution that replaces siloed, severity-based alerts with consolidated, risk-based guidance aligned with real-world clinical decision-making.

As community pharmacists continue to expand their responsibilities — including vaccinations, health screenings, and medication therapy management — reducing the cognitive burden associated with legacy alerting systems is becoming increasingly important. By standardizing responses across pharmacy locations and surfacing more actionable guidance, FDB Navigo helps support more consistent, efficient, and patient-centered care.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health, elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> <![CDATA[Your Operator Console Belongs in the Cloud. Let’s Talk at HCCT.]]> https://histalk.com/forum/showthread.php?tid=2301 Tue, 19 May 2026 22:36:32 +0000 MKothe]]> https://histalk.com/forum/showthread.php?tid=2301 book time with us here.

Why It Matters: Your Legacy System Is Costing You More Than You Think
On-prem operator consoles weren’t designed for today’s demands — multiple locations, workforce flexibility, and the integration complexity of a modern health system. If your team is still relying on aging hardware and paper on-call schedules, every day brings avoidable inefficiency, staffing constraints, and gaps in the patient experience.

PerfectServe’s cloud-based operator console was built specifically for hospitals and health systems. No proprietary hardware. No planned downtime for upgrades. Operators can work from anywhere — including during weather events or facility disruptions — while still having full access to real-time clinical directories, on-call schedules, and EHR data.

What You’ll See at Table 12: Purpose-Built for Healthcare Operator and Contact Centers
Every feature was designed with healthcare workflows in mind. We didn't just adapt our solution from a generic call center platform.

Single-Click Team Activations: Instantly activate your STEMI, stroke, code, and rapid response teams without searching through directories or paper schedules.
Unified Clinical Directory: One real-time source for on-call providers, care teams, departments, and patients — updated automatically, no manual maintenance.
Cloud-Based, Hardware-Free: Operators can work from anywhere. No proprietary hardware, automatic updates, and 99.99% uptime — no planned downtime for upgrades.
Two-Way Messaging with Read Receipts: Move beyond one-way pages. Send messages with patient context attached and confirm delivery and acknowledgement in real time.
250+ EHR & System Integrations: Connects out-of-the-box with your EHR, scheduling platforms, PBX, telephony, nurse call, and clinical communication systems.
Reporting & Analytics: Visualize queue activity, call history, agent performance, and response metrics — so you can manage your team with real data.

Who Benefits?
PerfectServe is offering a better experience for everyone in the chain:

IT Leaders: Simplify infrastructure. Reduce costs.
Contact Center Managers: Attract, retain, and empower your team.
Patients & Callers: Faster access, fewer transfers, better experience.

Single-Click Team Activations: Instantly activate your STEMI, stroke, code, and rapid response teams without searching through directories or paper schedules.
Unified Clinical Directory: One real-time source for on-call providers, care teams, departments, and patients — updated automatically, no manual maintenance.
Cloud-Based, Hardware-Free: Operators can work from anywhere. No proprietary hardware, automatic updates, and 99.99% uptime — no planned downtime for upgrades.
Two-Way Messaging with Read Receipts: Move beyond one-way pages. Send messages with patient context attached and confirm delivery and acknowledgement in real time.
250+ EHR & System Integrations: Connects out-of-the-box with your EHR, scheduling platforms, PBX, telephony, nurse call, and clinical communication systems.
Reporting & Analytics: Visualize queue activity, call history, agent performance, and response metrics — so you can manage your team with real data.

Who Benefits?
PerfectServe is offering a better experience for everyone in the chain:

IT Leaders: Simplify infrastructure. Reduce costs.
Contact Center Managers: Attract, retain, and empower your team.
Patients & Callers: Faster access, fewer transfers, better experience.

Reserve Time Now
Our exhibit schedule usually fills up during this conference. If you’re attending HCCT 2026 and want dedicated time with our team to see the product, ask your specific questions, and talk through what a transition from your current system would actually look like, make sure to reserve your spot now.

See you in Atlanta!]]> <![CDATA[PrognoCIS  Announces Strategic Collaboration with Global Payments to Launch PrognoPay]]> https://histalk.com/forum/showthread.php?tid=2300 Tue, 19 May 2026 16:47:36 +0000 Jasmine Torres]]> https://histalk.com/forum/showthread.php?tid=2300 PrognoCIS  Announces Strategic Collaboration with Global Payments to Launch PrognoPay
A native, end‑to‑end payments experience built into PrognoCIS, to accelerate financial performance and operational productivity.

Niagara Falls, NY – May 19, 2026 — PrognoCIS, a leading ambulatory Electronic Health Record (EHR) platform by Bizmatics, today announced the launch of PrognoPay, a modern payment solution embedded within PrognoCIS and powered by Global Payments, a global leader in payments technology. This strategic collaboration strengthens PrognoCIS’ commitment to product excellence by unifying clinical, administrative, and financial workflows into a single, seamless experience for providers, practices, and patients.

PrognoPay smoothly integrates payment processing directly into the clinical and administrative workflows of PrognoCIS, enabling healthcare practices to collect payments faster, reduce operational friction, and improve the overall patient financial experience—without relying on third‑party systems or standalone terminals. With this integration, PrognoCIS customers gain access to enterprise‑grade payment capabilities backed by Global Payments.

Designed for How Modern Practices Work and How Patients Pay
PrognoPay is built directly into PrognoCIS, allowing practices to manage patient billing, collections, and reconciliation without leaving the EHR. Payments post automatically, reducing errors and saving up to 8 hours per week in staff time that would otherwise be spent on manual reconciliation and follow-ups.
For patients, PrognoPay introduces convenient, digitally driven options that reflect evolving expectations. Features such as integrated text‑to‑pay, email payment requests, pay‑by‑link, recurring payments, and digital wallets make it easier for patients to pay balances quickly and securely—on their terms.
This patient-first approach helps practices improve collection rates, shorten payment cycles, and create a more transparent financial experience that builds trust and loyalty.

A Secure and Scalable Payments Foundation
PrognoPay delivers enterprise-grade security, PCI compliance, and reliability without adding complexity for providers. Sensitive payment data is securely managed while remaining tightly connected to patient accounts and workflows inside PrognoCIS. The result is a secure, scalable solution designed to support multilocation practices, specialty clinics, and growing healthcare organizations that demand consistency, performance, and confidence as they scale.

Quote:"PrognoPay represents a major step forward in our mission to simplify and modernize healthcare operations," said Derek Smith, Executive Vice President at Bizmatics. "By embedding payments natively into PrognoCIS and powering it with Global Payments, we are giving our customers a secure, scalable, and seamless way to manage payments directly inside their EHR—without disruption, without compromise."

"Healthcare organizations are increasingly looking for unified platforms that reduce friction across clinical, administrative, and financial workflows," Derek added. "This collaboration allows PrognoCIS clients to offer a modern, patient-friendly payment experience while maintaining the reliability and compliance required in healthcare."

Reinforcing Leadership Through Product and Customer Excellence
PrognoPay reflects PrognoCIS' continued focus on its three core pillars: product excellence, operational excellence, and customer excellence. By deeply integrating payments into the platform, PrognoCIS eliminates operational friction while delivering meaningful value where it matters most—time savings for staff, faster collections for practices, and ease of use for patients.

This advancement further strengthens PrognoCIS' position as a leader in the EHR space, focused on solving real business challenges for healthcare organizations that are growing and scaling in operation.

About Bizmatics
Bizmatics, Inc. is a leading healthcare technology company and the maker of PrognoCIS, a fully integrated Electronic Health Record (EHR) and Practice Management platform powering thousands of providers nationwide for over 20 years. PrognoCIS streamline workflows, strengthen revenue performance, and enhance patient care through a unified, cloud‑based platform designed to scale with practices as they grow. With PrognoAI, Bizmatics extends its commitment to innovation by equipping healthcare organizations with AI‑driven tools that enhance efficiency, improve accuracy, and support smarter clinical, financial, and operational decision‑making—enabling practices to operate with greater confidence and focus on patient care. For more information, visit prognocis.com and follow PrognoCIS on X, LinkedIn and Facebook.

About Global Payments
Global Payments Inc. is a leading payments technology company delivering innovative software and services to our customers globally. Our technologies, services and team member expertise allow us to provide a broad range of solutions that enable our customers to operate their businesses more efficiently across a variety of channels around the world. Headquartered in Georgia with approximately 27,000 team members worldwide, Global Payments is a Fortune 500® company and a member of the S&P 500 with worldwide reach spanning North America, Europe, Asia Pacific and Latin America.]]> <![CDATA[At WHA 2026: Join the Conversation on AI in Healthcare - Hosted by Qure.ai]]> https://histalk.com/forum/showthread.php?tid=2299 Thu, 14 May 2026 10:06:35 +0000 Atishay Jain]]> https://histalk.com/forum/showthread.php?tid=2299 Date: 19th May 2026, Tuesday
Venue: Intercontinental Hotel, Geneva
Time: 2 PM to 3 PM CET

Treatable conditions continue to be a death sentence in many parts of the world, simply because there are not enough doctors, and access to specialists remains deeply inequitable.
The divide is not new. The gap just keeps widening.
There is also a new reality. AI is already being used for screening, service delivery, and frontline support across health systems. The news of AI doctors and clinics may still be met with scepticism, but those working in the space know this shift is already underway. The most baffling part of all is the speed at which it is happening.
Is the AI doctor the answer the system never found?
What needs to be urgently built, governed, and trusted so that it works for those who need it most?
And is the system truly ready for the scale of change ahead?
In this session, we bring together government leaders, AI architects, and system builders shaping what comes next.

Featuring :

H.E. Budi Gunadi Sadikin
Minister of Health, Indonesia

Dr. Neil Buddy Shah
CEO, Clinton Health Access Initiative (CHAI), Chair of Anthropic’s Long-Term Benefit Trust

By invitation only. Limited seating. World Health Assembly Side Event · Geneva, May 2026
Link - Join now]]> Date: 19th May 2026, Tuesday
Venue: Intercontinental Hotel, Geneva
Time: 2 PM to 3 PM CET

Treatable conditions continue to be a death sentence in many parts of the world, simply because there are not enough doctors, and access to specialists remains deeply inequitable.
The divide is not new. The gap just keeps widening.
There is also a new reality. AI is already being used for screening, service delivery, and frontline support across health systems. The news of AI doctors and clinics may still be met with scepticism, but those working in the space know this shift is already underway. The most baffling part of all is the speed at which it is happening.
Is the AI doctor the answer the system never found?
What needs to be urgently built, governed, and trusted so that it works for those who need it most?
And is the system truly ready for the scale of change ahead?
In this session, we bring together government leaders, AI architects, and system builders shaping what comes next.

Featuring :

H.E. Budi Gunadi Sadikin
Minister of Health, Indonesia

Dr. Neil Buddy Shah
CEO, Clinton Health Access Initiative (CHAI), Chair of Anthropic’s Long-Term Benefit Trust

By invitation only. Limited seating. World Health Assembly Side Event · Geneva, May 2026
Link - Join now]]> <![CDATA[Surgery Partners' EHR: Transitioning to Expanse at $1M in Cost Avoidance]]> https://histalk.com/forum/showthread.php?tid=2298 Mon, 04 May 2026 17:21:14 +0000 BUram]]> https://histalk.com/forum/showthread.php?tid=2298 Surgery Partners and CereCore
Challenge
Surgery Partners operated 180+ locations across 35 states with fragmented EHR instances and limited centralized governance, which created inconsistent workflows, variable uptime risk, and high operational overhead, especially during acquisitions.

Results
CereCore helped Surgery Partners standardize MEDITECH across the enterprise, reduce variability in clinical workflows, and accelerate onboarding for newly acquired facilities. By centralizing hosting, we improved uptime and simplified patching and upgrades, enabling Surgery Partners’ IT team to focus on strategic initiatives rather than routine maintenance.

10
Hospitals migrated in 10 months
99.8%
Patching compliance average
13
Locations on centralized hosting

About the Provider
Surgery Partners operates over 180 ancillary service locations in 35 states, including ambulatory surgery centers (ASCs) and surgical hospitals. Treating over 600,000 patients annually, the organization is a leader in the shift toward high-quality, cost-effective surgical care. Their mission is driven by strategic partnerships that enhance patient quality of life through technological and operational excellence.

Centralizing Infrastructure for Enterprise Scale
The partnership matured into a comprehensive hosting services agreement where CereCore became the primary provider for MEDITECH applications. By migrating surgical hospitals on MEDITECH 6.x and Expanse to a centralized data center in Nashville, Surgery Partners eliminated the burden of managing local server environments. This shift allowed the organization to standardize its technology stack, ensuring that every facility—regardless of its legacy system—operated on a reliable and secure platform.

Key Outcomes:

Accelerated Migration Timeline: Successfully transitioned 10 surgical hospitals to a centralized data center within a strict 10-month window with zero downtime.
Elite Security Standards: Achieved and maintained a 99.8% patching compliance average across all OS servers and third-party applications throughout 2023.
Operational Consistency: Established standardized monthly patching and data backup cycles for every facility within four weeks of their migration.
Infrastructure Optimization: Implemented proactive resource monitoring (storage and server) to ensure 24/7 system availability and efficient application performance.
Informed Decision Support: Delivered monthly infrastructure reporting to Surgery Partners leadership, providing transparency into hosted environment changes and growth capacity.

Standardized Maintenance and Reliability
A critical component of the hosting transition was the implementation of rigorous patching and data backup cycles. CereCore established these standards within four weeks of the transition for each facility. Throughout 2023, the application management and infrastructure teams maintained a 99.8% patching compliance average. This proactive approach to server health ensures that Surgery Partners’ clinical systems remain secure against vulnerabilities while maintaining high availability for providers.

Strategic Resource Reallocation
By leveraging CereCore for core IT operations, Surgery Partners’ leadership was able to reorganize internal IT teams. Freed from the day-to-day "heavy lifting" of infrastructure maintenance, internal resources shifted their focus to IT strategy and innovation. This realignment has been instrumental in supporting the company’s long-term growth plan and ensuring that technology serves as a catalyst for clinical success rather than an operational bottleneck.

"I have seen the value first-hand in a partnership. Sometimes as an organization you have to take a step back and determine whether we should develop this as a core competency. Or, should we leverage a partner that’s already solved for this and can do it at scale so that we can focus on areas we do want to be our core competency."

Varun Gadhok | CIO, Surgery Partners

Result
By centralizing IT infrastructure, Surgery Partners achieved the scale necessary to support its growth trajectory. The migration to the Nashville data center provided a reliable, high-performing environment that reduced the maintenance burden on internal staff. With a 99.8% patching compliance rate, the organization now operates with improved security and reliability, providing a stable foundation for future acquisitions and technological innovation.

Ready to get started? Contact us.]]> Surgery Partners and CereCore
Challenge
Surgery Partners operated 180+ locations across 35 states with fragmented EHR instances and limited centralized governance, which created inconsistent workflows, variable uptime risk, and high operational overhead, especially during acquisitions.

Results
CereCore helped Surgery Partners standardize MEDITECH across the enterprise, reduce variability in clinical workflows, and accelerate onboarding for newly acquired facilities. By centralizing hosting, we improved uptime and simplified patching and upgrades, enabling Surgery Partners’ IT team to focus on strategic initiatives rather than routine maintenance.

10
Hospitals migrated in 10 months
99.8%
Patching compliance average
13
Locations on centralized hosting

About the Provider
Surgery Partners operates over 180 ancillary service locations in 35 states, including ambulatory surgery centers (ASCs) and surgical hospitals. Treating over 600,000 patients annually, the organization is a leader in the shift toward high-quality, cost-effective surgical care. Their mission is driven by strategic partnerships that enhance patient quality of life through technological and operational excellence.

Centralizing Infrastructure for Enterprise Scale
The partnership matured into a comprehensive hosting services agreement where CereCore became the primary provider for MEDITECH applications. By migrating surgical hospitals on MEDITECH 6.x and Expanse to a centralized data center in Nashville, Surgery Partners eliminated the burden of managing local server environments. This shift allowed the organization to standardize its technology stack, ensuring that every facility—regardless of its legacy system—operated on a reliable and secure platform.

Key Outcomes:

Accelerated Migration Timeline: Successfully transitioned 10 surgical hospitals to a centralized data center within a strict 10-month window with zero downtime.
Elite Security Standards: Achieved and maintained a 99.8% patching compliance average across all OS servers and third-party applications throughout 2023.
Operational Consistency: Established standardized monthly patching and data backup cycles for every facility within four weeks of their migration.
Infrastructure Optimization: Implemented proactive resource monitoring (storage and server) to ensure 24/7 system availability and efficient application performance.
Informed Decision Support: Delivered monthly infrastructure reporting to Surgery Partners leadership, providing transparency into hosted environment changes and growth capacity.

New module applies NDC-level drug density data to help health systems detect compounding discrepancies earlier

SOUTH SAN FRANCISCO, Calif., April 30, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced the launch of its new gravimetric module, designed to help pharmacies improve the safety, accuracy, and efficiency of sterile compounding workflows for high-risk, high-cost medications.

The FDB Gravimetric Drug Density Module is a new clinical module contained within FDB MedKnowledge®, the healthcare industry's most widely integrated drug database used by clinicians to make better medication decisions at the point of care. FDB MedKnowledge combines descriptive drug information, unique identifiers, and pricing data with an extensive array of clinical decision support modules to help pharmacists, physicians, nurses and other medical professionals avoid medication errors, prevent adverse drug events, reduce drug-related expenses, and improve the quality of patient care.

The FDB Gravimetric Drug Density Module delivers normalized drug density data at the National Drug Code (NDC) level to support gravimetric verification during infusion medication preparation. By enabling clinical systems to calculate expected weights for compounded preparations and compare them against measured values, the module provides an additional layer of validation beyond traditional visual and volumetric checks. This capability is especially critical for high-risk, high-cost oncology therapies where minor deviations in dose can have significant clinical consequences.

"Health systems are looking for practical ways to advance pharmacy safety while supporting staff efficiency and compounding scalability," said Chirag Patel, PharmD, MBA, director of product management at FDB. "Our new gravimetric content module extends FDB's medication knowledge into critical infusion workflows where accuracy, consistency, and trust matter every time a dose is prepared."

Higher Detection of Preparation Errors

Clinical evidence supports the value of gravimetric preparation in identifying compounding discrepancies that may otherwise go undetected. In a peer-reviewed study published in the American Journal of Health-System Pharmacy, gravimetric verification increased detection of compounding errors by nearly 90-fold, identifying discrepancies in more than 40% of preparations compared with less than 1% using traditional methods. The study also found that pharmacy staff perceived gravimetric workflows as the safest and most accurate approach to producing compounded sterile products.

This evidence reinforces the role of weight-based verification as a critical safeguard for high-risk inpatient medications, particularly in complex, high-volume pharmacy environments.

Overcoming Safety and Workflow Challenges

Manual IV compounding verification relies heavily on visual inspection and volumetric measurement, which can be time-intensive. Traditional visual verification requires pharmacists to suit up in full cleanroom personal protective equipment and enter the sterile IV compounding area to conduct in-person checks alongside technicians.

Conversely, gravimetric workflows support verification through captured weight measurements and images that can be reviewed outside the cleanroom while maintaining accuracy and documentation, helping pharmacies identify discrepancies early in the process.

The FDB Gravimetric Drug Density Module supports this approach by providing curated, maintained drug-density data that health systems would otherwise need to source, calculate, and manage internally. By centralizing this data, FDB helps reduce implementation complexity while supporting consistent, repeatable verification practices across pharmacy operations.

In addition to safety benefits, gravimetric workflows can reduce the need for pharmacists to remain physically present in cleanroom environments for manual checks, allowing them to focus on clinical activities while maintaining oversight through digital verification, audit trails, and alerts.

Integrating Trusted Medication Knowledge

The FDB Gravimetric Drug Density Module is delivered as a premium offering within FDB MedKnowledge and is also available as a standalone data solution for organizations and technology partners that require NDC-level density data independent of a broader medication knowledge platform.

The initial release focuses on injectable antineoplastic medications, with plans to expand coverage over time. The content is designed to support integration with both inpatient and outpatient pharmacy systems that are adopting or expanding sterile gravimetric compounding workflows.

The launch reflects FDB's broader strategy to extend its medication knowledge into emerging areas of clinical and operational need, supporting healthcare organizations as they modernize pharmacy operations and address workforce pressures while maintaining rigorous safety standards.

"Gravimetric verification represents an important step forward in how health systems approach safety and quality in sterile compounding," said Patel. "By delivering trusted, NDC-level density data that is ready for use at scale, FDB is helping pharmacies reduce manual burden, strengthen safeguards for high-risk medications, and move toward more automated, reliable workflows."

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecommunications.ai]]> FDB Launches Gravimetric Content to Strengthen Safety and Accuracy in IV Medication Compounding

New module applies NDC-level drug density data to help health systems detect compounding discrepancies earlier

SOUTH SAN FRANCISCO, Calif., April 30, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, today announced the launch of its new gravimetric module, designed to help pharmacies improve the safety, accuracy, and efficiency of sterile compounding workflows for high-risk, high-cost medications.

The FDB Gravimetric Drug Density Module is a new clinical module contained within FDB MedKnowledge®, the healthcare industry's most widely integrated drug database used by clinicians to make better medication decisions at the point of care. FDB MedKnowledge combines descriptive drug information, unique identifiers, and pricing data with an extensive array of clinical decision support modules to help pharmacists, physicians, nurses and other medical professionals avoid medication errors, prevent adverse drug events, reduce drug-related expenses, and improve the quality of patient care.

The FDB Gravimetric Drug Density Module delivers normalized drug density data at the National Drug Code (NDC) level to support gravimetric verification during infusion medication preparation. By enabling clinical systems to calculate expected weights for compounded preparations and compare them against measured values, the module provides an additional layer of validation beyond traditional visual and volumetric checks. This capability is especially critical for high-risk, high-cost oncology therapies where minor deviations in dose can have significant clinical consequences.

"Health systems are looking for practical ways to advance pharmacy safety while supporting staff efficiency and compounding scalability," said Chirag Patel, PharmD, MBA, director of product management at FDB. "Our new gravimetric content module extends FDB's medication knowledge into critical infusion workflows where accuracy, consistency, and trust matter every time a dose is prepared."

Higher Detection of Preparation Errors

Clinical evidence supports the value of gravimetric preparation in identifying compounding discrepancies that may otherwise go undetected. In a peer-reviewed study published in the American Journal of Health-System Pharmacy, gravimetric verification increased detection of compounding errors by nearly 90-fold, identifying discrepancies in more than 40% of preparations compared with less than 1% using traditional methods. The study also found that pharmacy staff perceived gravimetric workflows as the safest and most accurate approach to producing compounded sterile products.

This evidence reinforces the role of weight-based verification as a critical safeguard for high-risk inpatient medications, particularly in complex, high-volume pharmacy environments.

Overcoming Safety and Workflow Challenges

Manual IV compounding verification relies heavily on visual inspection and volumetric measurement, which can be time-intensive. Traditional visual verification requires pharmacists to suit up in full cleanroom personal protective equipment and enter the sterile IV compounding area to conduct in-person checks alongside technicians.

Conversely, gravimetric workflows support verification through captured weight measurements and images that can be reviewed outside the cleanroom while maintaining accuracy and documentation, helping pharmacies identify discrepancies early in the process.

The FDB Gravimetric Drug Density Module supports this approach by providing curated, maintained drug-density data that health systems would otherwise need to source, calculate, and manage internally. By centralizing this data, FDB helps reduce implementation complexity while supporting consistent, repeatable verification practices across pharmacy operations.

In addition to safety benefits, gravimetric workflows can reduce the need for pharmacists to remain physically present in cleanroom environments for manual checks, allowing them to focus on clinical activities while maintaining oversight through digital verification, audit trails, and alerts.

Integrating Trusted Medication Knowledge

The FDB Gravimetric Drug Density Module is delivered as a premium offering within FDB MedKnowledge and is also available as a standalone data solution for organizations and technology partners that require NDC-level density data independent of a broader medication knowledge platform.

The initial release focuses on injectable antineoplastic medications, with plans to expand coverage over time. The content is designed to support integration with both inpatient and outpatient pharmacy systems that are adopting or expanding sterile gravimetric compounding workflows.

The launch reflects FDB's broader strategy to extend its medication knowledge into emerging areas of clinical and operational need, supporting healthcare organizations as they modernize pharmacy operations and address workforce pressures while maintaining rigorous safety standards.

"Gravimetric verification represents an important step forward in how health systems approach safety and quality in sterile compounding," said Patel. "By delivering trusted, NDC-level density data that is ready for use at scale, FDB is helping pharmacies reduce manual burden, strengthen safeguards for high-risk medications, and move toward more automated, reliable workflows."

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB's solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecommunications.ai]]> <![CDATA[FDB Expert to Highlight AI's Emerging Impact on ePrescribing Workflows During NCPDP]]> https://histalk.com/forum/showthread.php?tid=2296 Wed, 29 Apr 2026 14:09:21 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2296 FDB Expert to Highlight AI's Emerging Impact on ePrescribing Workflows During NCPDP Annual Conference

Educational Track Session will describe how innovations can improve accuracy, reduce manual steps, and enhance interoperability across prescribing and pharmacy settings

SOUTH SAN FRANCISCO, Calif., April 29, 2026 -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, announced that Brad Engels, senior product manager at FDB, will share insights on how AI is reshaping prescription processing across the care continuum at the National Council for Prescription Drug Programs (NCPDP) 2026 Annual Technology & Business Conference.

The educational track session, titled "First Steps of AI's Revolutionary Impact on Prescription Processing," will take place on Tuesday, May 5, from 9:15 a.m. to 10:15 a.m. at the NCPDP Annual Conference 2026 in Scottsdale, Ariz.

The conference, themed "The Heart of Health Information Exchange: Powering Interoperable Futures," takes place May 4-6 at the Westin Kierland Resort & Spa in Scottsdale.

"Prescription processing has long been burdened by manual steps that consume clinician and pharmacist time, introduce variability, and create friction across the care continuum," said Engels. "AI offers a meaningful opportunity to address these challenges by bringing structure, accuracy, and efficiency to the way prescriptions are created, transmitted, and fulfilled. We are excited to explore these possibilities with the NCPDP community."

The session will examine how structured content facilitated by AI can drive greater interoperability, automation, and better outcomes for prescribers, pharmacies, and patients when integrated with NCPDP SCRIPT transactions such as NewRx, RxChange, CancelRx, and RxFill.

Engels will explore how AI is enhancing accuracy, speed, and patient care at multiple stages of the prescribing and dispensing process. On the prescriber side, ambient AI technologies are emerging that can capture medications, allergies, and prescriber intent during patient encounters to pre-populate prescriptions, interpret SIG instructions, normalize dosing, and improve consistency. The result is cleaner NewRx messages, reducing the need for pharmacy callbacks and rework.

On the pharmacy side, AI-driven natural language processing capabilities are beginning to support SIG translation, dose normalization, days-supply calculation, and drug-utilization review cues. These capabilities can help streamline pharmacy processing, reduce RxChange cycles, and mitigate exposure to pharmacy benefit manager audits.

Additional insights will be shared during the session by Rachel DiVincenzo, PharmD, senior manager of health and wellness systems operations at Kroger Health.

FDB has been at the forefront of the ePrescribing evolution, building on decades of drug knowledge expertise to develop AI-native capabilities that support medication workflow automation. The company launched the first new ePrescribing network in two decades when it rolled out FDB Vela™ several years ago. Recently FDB introduced MedProof MCP™ Model Context Protocol (MCP) server technology for ePrescribing, along with intelligent workflow tools designed to help clinicians and pharmacists reduce administrative burden while maintaining clinical accuracy.

FDB MedProof MCP is an AI-native MCP integration framework that enables technology teams to confidently connect agentic systems and applications to standardized medication intelligence delivered in a patient-specific clinical context. FDB also offers FDB Script Agent™, a prescription automation agent that leverages ambient listening data to auto-queue structured prescription orders for clinician review, and FDB VerifyAssist™, a pharmacy workflow assistant that automatically surfaces the most relevant drug and patient data during medication order verification. This helps hospital pharmacists quickly identify orders that warrant closer review.

These capabilities reflect the broader trajectory that will be explored at NCPDP: how AI-driven structure and automation across the prescription lifecycle can reduce friction, improve accuracy, and deliver better outcomes for prescribers, pharmacies, and patients.

Learn more about FDB Vela, FDB MedProof MCP, FDB Script Agent and FDB VerifyAssist.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for rigorous quality control, deep clinical expertise, and a collaborative approach, FDB helps improve patient safety, streamline operations, and enhance health outcomes. FDB's comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For more information, visit www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety, and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies — FDB, Homecare Homebase, MCG, MHK, QGenda, and Zynx Health — elevate care by informing and empowering participants across the health journey. Learn more at www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

Media Contact
Supreme Communications for FDB
FDBPR@supremecomms.ai]]> <![CDATA[Meet Qure.ai at 2026 ASCO® Annual Meeting | Booth #IH12]]> https://histalk.com/forum/showthread.php?tid=2295 Tue, 21 Apr 2026 08:49:48 +0000 Atishay Jain]]> https://histalk.com/forum/showthread.php?tid=2295 Driving Stage Shift in Oncology with AI: Qure.ai at 2026 ASCO® Annual Meeting

At the ASCO 2026 Annual Meeting, Qure.ai is spotlighting how AI can enable a meaningful stage shift in oncology by moving care from reactive to proactive. By turning clinical data into actionable insights, Qure.ai helps identify patients earlier, accelerate intervention, and support more timely access to treatment, addressing one of the most critical gaps in cancer care today.

A key focus is the role of AI powered imaging biomarkers in bridging the gap between clinical trials and real-world impact. Qure.ai demonstrates how these biomarkers & guideline concorded workflows can be operationalized at scale to support patient identification, improve stratification, and enhance decision-making across care teams. This ability to integrate seamlessly into clinical workflows ensures that opportunities for early action are not missed.

With 26 FDA-cleared indications and deployments across millions of patients globally, Qure.ai continues to deliver clinically validated, scalable AI solutions. Visit Booth #IH12 at ASCO 2026 to explore how AI-driven patient identification and coordinated care can enable early diagnosis, reduce delays, and ultimately improve patient outcomes.

To know more, visit: https://www.qure.ai/events/asco-2026]]> Driving Stage Shift in Oncology with AI: Qure.ai at 2026 ASCO® Annual Meeting

At the ASCO 2026 Annual Meeting, Qure.ai is spotlighting how AI can enable a meaningful stage shift in oncology by moving care from reactive to proactive. By turning clinical data into actionable insights, Qure.ai helps identify patients earlier, accelerate intervention, and support more timely access to treatment, addressing one of the most critical gaps in cancer care today.

A key focus is the role of AI powered imaging biomarkers in bridging the gap between clinical trials and real-world impact. Qure.ai demonstrates how these biomarkers & guideline concorded workflows can be operationalized at scale to support patient identification, improve stratification, and enhance decision-making across care teams. This ability to integrate seamlessly into clinical workflows ensures that opportunities for early action are not missed.

With 26 FDA-cleared indications and deployments across millions of patients globally, Qure.ai continues to deliver clinically validated, scalable AI solutions. Visit Booth #IH12 at ASCO 2026 to explore how AI-driven patient identification and coordinated care can enable early diagnosis, reduce delays, and ultimately improve patient outcomes.

To know more, visit: https://www.qure.ai/events/asco-2026]]> <![CDATA[Join the Bizmatics Team at AOHC Conference - Booth #511]]> https://histalk.com/forum/showthread.php?tid=2290 Thu, 16 Apr 2026 17:53:18 +0000 Jasmine Torres]]> https://histalk.com/forum/showthread.php?tid=2290 AOHC Conference, April 19–22, 2026, in Chicago, IL, where we’ll be showcasing our AI-integrated EHR, PrognoCIS. Visit us at Booth #511 to see how PrognoCIS streamlines occupational health workflows, supports compliance, and improves efficiency. We look forward to connecting and sharing what’s next in EHR innovation.

Don’t miss out, surprise giveaways await! Stop by, or if you’re headed to the conference, learn more at: https://buff.ly/bRVMvgL

[Image: AOHC-PrognoCIS-EHR.png]

]]> AOHC Conference, April 19–22, 2026, in Chicago, IL, where we’ll be showcasing our AI-integrated EHR, PrognoCIS. Visit us at Booth #511 to see how PrognoCIS streamlines occupational health workflows, supports compliance, and improves efficiency. We look forward to connecting and sharing what’s next in EHR innovation.

Don’t miss out, surprise giveaways await! Stop by, or if you’re headed to the conference, learn more at: https://buff.ly/bRVMvgL

[Image: AOHC-PrognoCIS-EHR.png]

]]> <![CDATA[Register Now | 5th Annual Connect Social Care Summit - May 13 & 14]]> https://histalk.com/forum/showthread.php?tid=2291 Tue, 14 Apr 2026 17:12:35 +0000 Marketing at Findhelp]]> https://histalk.com/forum/showthread.php?tid=2291 On May 13 & 14, 2026 we’re hosting our sixth annual user conference, Connect: A Social Care Summit! Free to attend, this virtual Summit will bring together 2,000+ leaders from social care, healthcare, government, nonprofits, and more.

Join us for live presentations, discussions, and actionable insights as we work to build resilient solutions to address today’s most pressing social care needs. With more than 40 sessions to choose from and featuring a keynote with Teri Takai, you can curate your Summit schedule to fit the needs of your organization—whether you’re just getting started with your social care strategy or looking to expand a successful program.

Snag your spot —> Register for free

[Image: HIStalk%20Connect%20Summet%20image%20-%2...0board.png]

]]> On May 13 & 14, 2026 we’re hosting our sixth annual user conference, Connect: A Social Care Summit! Free to attend, this virtual Summit will bring together 2,000+ leaders from social care, healthcare, government, nonprofits, and more.

Join us for live presentations, discussions, and actionable insights as we work to build resilient solutions to address today’s most pressing social care needs. With more than 40 sessions to choose from and featuring a keynote with Teri Takai, you can curate your Summit schedule to fit the needs of your organization—whether you’re just getting started with your social care strategy or looking to expand a successful program.

Snag your spot —> Register for free

]]> <![CDATA[RxWallet® Goes Live on FDB Vela™]]> https://histalk.com/forum/showthread.php?tid=2289 Thu, 09 Apr 2026 19:22:12 +0000 Margaret Kelly]]> https://histalk.com/forum/showthread.php?tid=2289 RxWallet® Goes Live on FDB Vela™, Expanding Real-Time Prescription Price Transparency for Consumers

ePrescribing network integration of RxEOB smartphone app enables consumers to view prescription costs and pharmacy options before filling medications

SOUTH SAN FRANCISCO, CA, and RICHMOND, VA, April 9, 2026 — FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, and RxEOB, a leading provider of online communication and application tools for pharmacy benefit payers and managers, announced that the RxWallet® consumer smartphone app is now live on the FDB Vela™ cloud-native electronic prescribing (ePrescribing) network.

The go-live follows the companies’ earlier announcement of an agreement to integrate RxWallet with the FDB Vela network. The launch enables consumers to view personalized prescription price information, compare pharmacy options, and make more informed decisions about where to fill medications before arriving at the pharmacy counter. FDB Vela is designed to support secure, resilient connectivity across the prescribing ecosystem. By enabling standards-based communication among prescribers, pharmacies, and payers, the network supports the development of new applications that deliver greater transparency, operational efficiency, and patient engagement throughout the prescription journey.

“Electronic prescribing infrastructure plays an important role in connecting prescribers, pharmacies, payers, and patients through trusted prescription data,” said David Delaney, MD, president of FDB. “The launch of RxWallet on FDB Vela demonstrates how modern prescribing networks can facilitate greater transparency and patient choice by delivering timely cost and coverage information directly to consumers during the prescription process.”

RxWallet receives prescription and benefits information through the FDB Vela ePrescribing network, which supports real-time communication among prescribers, pharmacies, and payers. Through a mobile experience designed to give consumers pricing visibility, RxWallet enables patients to select a pharmacy based on potential out-of-pocket costs, available discounts, and location convenience before a prescription is directed to a particular pharmacy and filled.

“Turning this collaboration into a live, consumer-facing experience is a major milestone in our mission to give people a simple, reliable way to access affordable prescriptions,” said Robert Oscar, CEO and founder of RxEOB. “Now, with FDB Vela powering RxWallet behind the scenes, consumers can see their potential out-of-pocket costs and compare options on their phones, which helps them avoid financial surprises at the pharmacy and stay on therapy.”

Prescription affordability continues to influence whether patients initiate or maintain treatment. New research from the Kaiser Family Foundation shows that 32% of Americans are “very worried” about being able to afford their healthcare, highlighting prescription drugs as a leading cost concern. Delivering price transparency to consumers earlier in the prescribing process can help patients understand their options and reduce the likelihood of prescription abandonment.

Through the integration with FDB Vela, consumers whose prescribers participate in the network gain access to personalized prescription pricing estimates, real-time discount and coupon availability, and the ability to route prescriptions to a preferred pharmacy based on cost and convenience.

The launch of RxWallet on FDB Vela underscores the ongoing momentum for FDB Vela as a transformative force in the electronic prescribing landscape. By providing a cloud-native network that connects pharmacies, prescribers, and payers, FDB Vela enables organizations like RxEOB to build next-generation patient tools on a foundation of reliable, real-time clinical and transactional data. RxWallet is among a growing portfolio of solutions leveraging this infrastructure to reshape how Americans interact with the healthcare system.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. FDB Vela™ is a cloud-native electronic prescribing network that enables the seamless flow of critical medication prescription information, benefits verification, and clinical decision support between prescribers, payers, and pharmacies.

To learn more about FDB Vela, please visit https://www.fdbvela.com. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies — FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health — elevate care by informing and empowering participants across the health journey. To learn more, visit www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About RxEOB
RxEOB is a health information technology company with deep roots in pharmacy, medical, and related data. For 25 years, the company has helped health plans and pharmacy benefit managers engage their members to optimize the clinical and financial effectiveness of prescription benefit programs through intelligent communications. From predictive pricing and preferred alternatives to algorithms that account for individualized benefit coverage, RxEOB leverages patient-specific characteristics including social factors, demographic data, behavioral and claim history to provide relevant communications and trusted engagement programs while maintaining strict adherence to regulatory compliance.

Media Contacts
Supreme Communications for FDB
FDBPR@supremecomms.ai

RxEOB
sales@rxeob.com]]> RxWallet® Goes Live on FDB Vela™, Expanding Real-Time Prescription Price Transparency for Consumers

ePrescribing network integration of RxEOB smartphone app enables consumers to view prescription costs and pharmacy options before filling medications

SOUTH SAN FRANCISCO, CA, and RICHMOND, VA, April 9, 2026 — FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, and RxEOB, a leading provider of online communication and application tools for pharmacy benefit payers and managers, announced that the RxWallet® consumer smartphone app is now live on the FDB Vela™ cloud-native electronic prescribing (ePrescribing) network.

The go-live follows the companies’ earlier announcement of an agreement to integrate RxWallet with the FDB Vela network. The launch enables consumers to view personalized prescription price information, compare pharmacy options, and make more informed decisions about where to fill medications before arriving at the pharmacy counter. FDB Vela is designed to support secure, resilient connectivity across the prescribing ecosystem. By enabling standards-based communication among prescribers, pharmacies, and payers, the network supports the development of new applications that deliver greater transparency, operational efficiency, and patient engagement throughout the prescription journey.

“Electronic prescribing infrastructure plays an important role in connecting prescribers, pharmacies, payers, and patients through trusted prescription data,” said David Delaney, MD, president of FDB. “The launch of RxWallet on FDB Vela demonstrates how modern prescribing networks can facilitate greater transparency and patient choice by delivering timely cost and coverage information directly to consumers during the prescription process.”

RxWallet receives prescription and benefits information through the FDB Vela ePrescribing network, which supports real-time communication among prescribers, pharmacies, and payers. Through a mobile experience designed to give consumers pricing visibility, RxWallet enables patients to select a pharmacy based on potential out-of-pocket costs, available discounts, and location convenience before a prescription is directed to a particular pharmacy and filled.

“Turning this collaboration into a live, consumer-facing experience is a major milestone in our mission to give people a simple, reliable way to access affordable prescriptions,” said Robert Oscar, CEO and founder of RxEOB. “Now, with FDB Vela powering RxWallet behind the scenes, consumers can see their potential out-of-pocket costs and compare options on their phones, which helps them avoid financial surprises at the pharmacy and stay on therapy.”

Prescription affordability continues to influence whether patients initiate or maintain treatment. New research from the Kaiser Family Foundation shows that 32% of Americans are “very worried” about being able to afford their healthcare, highlighting prescription drugs as a leading cost concern. Delivering price transparency to consumers earlier in the prescribing process can help patients understand their options and reduce the likelihood of prescription abandonment.

Through the integration with FDB Vela, consumers whose prescribers participate in the network gain access to personalized prescription pricing estimates, real-time discount and coupon availability, and the ability to route prescriptions to a preferred pharmacy based on cost and convenience.

The launch of RxWallet on FDB Vela underscores the ongoing momentum for FDB Vela as a transformative force in the electronic prescribing landscape. By providing a cloud-native network that connects pharmacies, prescribers, and payers, FDB Vela enables organizations like RxEOB to build next-generation patient tools on a foundation of reliable, real-time clinical and transactional data. RxWallet is among a growing portfolio of solutions leveraging this infrastructure to reshape how Americans interact with the healthcare system.

About FDB
FDB (First Databank) delivers clinically robust, workflow-integrated drug knowledge that is intuitive, patient-specific, and actionable, enabling more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline operations, and enhance health outcomes. Our comprehensive drug databases and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. FDB Vela™ is a cloud-native electronic prescribing network that enables the seamless flow of critical medication prescription information, benefits verification, and clinical decision support between prescribers, payers, and pharmacies.

To learn more about FDB Vela, please visit https://www.fdbvela.com. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health
The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies — FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health — elevate care by informing and empowering participants across the health journey. To learn more, visit www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About RxEOB
RxEOB is a health information technology company with deep roots in pharmacy, medical, and related data. For 25 years, the company has helped health plans and pharmacy benefit managers engage their members to optimize the clinical and financial effectiveness of prescription benefit programs through intelligent communications. From predictive pricing and preferred alternatives to algorithms that account for individualized benefit coverage, RxEOB leverages patient-specific characteristics including social factors, demographic data, behavioral and claim history to provide relevant communications and trusted engagement programs while maintaining strict adherence to regulatory compliance.

Media Contacts
Supreme Communications for FDB
FDBPR@supremecomms.ai

RxEOB
sales@rxeob.com]]> <![CDATA[CereCore Achieves Outstanding 2026 KLAS Rating in Managed IT Services]]> https://histalk.com/forum/showthread.php?tid=2288 Mon, 06 Apr 2026 16:00:35 +0000 BUram]]> https://histalk.com/forum/showthread.php?tid=2288 CereCore Achieves Outstanding 2026 KLAS Rating in Managed IT Services

CereCore outscores professional services category average in every pillar

NASHVILLE, Tenn. – CereCore®,  a leading provider of healthcare IT services, announces an exceptional achievement in 2026 KLAS ratings for the Managed IT Services segment and high scores (four A’s) across all customer experience pillars. The company has received an impressive overall KLAS score of 93, marking the third year to be highly rated in this competitive category. KLAS Research, a research organization that helps healthcare providers make informed technology decisions by offering impartial vendor performance information, recognizes CereCore's dedication to excellence and innovation in delivering top-notch IT services to healthcare organizations.

The Best in KLAS report  provides meticulous analysis of client feedback gathered over the course of a year, assigning weighted letter grades to measure five critical customer experience pillars—Loyalty, Operations, Services, Relationship and Value.  

CereCore received four A’s in the KLAS customer experience pillars with highest marks in the Loyalty and Value pillars. Clients responded “Yes” 100% of the time to these binary questions: 

+ Avoids charging for every little thing?

+ Would you buy again? 

CereCore was honored to receive an 8 or 9 (out of 9) from 84% of respondents. 

"At CereCore, we are committed to serving clients with consistent delivery of high-quality IT services for healthcare. We are grateful for our clients as we work together with compassion and clear understanding of the impact that IT services have on clinical teams and the quality of care they deliver,” said Curtis Watkins, president and CEO at CereCore.

CereCore takes this opportunity to express gratitude to valued clients for their trust and partnership. Here are client quotes from the  2026 Best in KLAS Awards – Software and Services report:

Operations, Services
"CereCore jumps in with both feet and never hesitates. We never get a no; the response is always that they will figure out how we can do something. The firm is very transparent, especially through contracting, and we value that highly. When we switched service desks, they onboarded us so smoothly that we did not even have a blip. Normally, we see a spike in call volume, hold times, or backlogs during a transition, but we saw none of that. Looking at our reports, someone would never be able to tell when the change happened, and that speaks to how seamless CereCore made the entire process." 5/5 stars | VP/Other Executive, Dec 2025

Relationship, Value
"CereCore uses tiered volume pricing, and when we consistently came in under our forecast volume, they adjusted our pricing accordingly. The contract did not require the firm to do that, but it was the right thing to do. I did not even have to ask; they proactively notified me of the trend and told me they were moving us to a lower pricing tier." 5/5 stars | VP/Other Executive, Dec 2025

Loyalty, Value
"We have been happy with CereCore and are working well with them, so we really aren't looking at changing at this point. We brought CereCore in, really liked their product, really liked their model, and liked the way that they were planning on doing things, and there was a really good price point for us. We have been pleased ever since." 5/5 stars | Director, Dec 2025

“Feedback from clients about our partnership, as shared with KLAS or in our regular dealings with one another, inspires us and helps us identify opportunities to continually improve how we serve as managed IT services partners with some of healthcare’s top organizations,” said Watkins.

For more information on CereCore’s KLAS ranking, view the complete 2026 Best in KLAS Awards – Software and Services report.

About KLAS
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.]]> CereCore Achieves Outstanding 2026 KLAS Rating in Managed IT Services

CereCore outscores professional services category average in every pillar

NASHVILLE, Tenn. – CereCore®,  a leading provider of healthcare IT services, announces an exceptional achievement in 2026 KLAS ratings for the Managed IT Services segment and high scores (four A’s) across all customer experience pillars. The company has received an impressive overall KLAS score of 93, marking the third year to be highly rated in this competitive category. KLAS Research, a research organization that helps healthcare providers make informed technology decisions by offering impartial vendor performance information, recognizes CereCore's dedication to excellence and innovation in delivering top-notch IT services to healthcare organizations.

The Best in KLAS report  provides meticulous analysis of client feedback gathered over the course of a year, assigning weighted letter grades to measure five critical customer experience pillars—Loyalty, Operations, Services, Relationship and Value.  

CereCore received four A’s in the KLAS customer experience pillars with highest marks in the Loyalty and Value pillars. Clients responded “Yes” 100% of the time to these binary questions: 

+ Avoids charging for every little thing?

+ Would you buy again? 

CereCore was honored to receive an 8 or 9 (out of 9) from 84% of respondents. 

"At CereCore, we are committed to serving clients with consistent delivery of high-quality IT services for healthcare. We are grateful for our clients as we work together with compassion and clear understanding of the impact that IT services have on clinical teams and the quality of care they deliver,” said Curtis Watkins, president and CEO at CereCore.

CereCore takes this opportunity to express gratitude to valued clients for their trust and partnership. Here are client quotes from the  2026 Best in KLAS Awards – Software and Services report:

Operations, Services
"CereCore jumps in with both feet and never hesitates. We never get a no; the response is always that they will figure out how we can do something. The firm is very transparent, especially through contracting, and we value that highly. When we switched service desks, they onboarded us so smoothly that we did not even have a blip. Normally, we see a spike in call volume, hold times, or backlogs during a transition, but we saw none of that. Looking at our reports, someone would never be able to tell when the change happened, and that speaks to how seamless CereCore made the entire process." 5/5 stars | VP/Other Executive, Dec 2025

Relationship, Value
"CereCore uses tiered volume pricing, and when we consistently came in under our forecast volume, they adjusted our pricing accordingly. The contract did not require the firm to do that, but it was the right thing to do. I did not even have to ask; they proactively notified me of the trend and told me they were moving us to a lower pricing tier." 5/5 stars | VP/Other Executive, Dec 2025

Loyalty, Value
"We have been happy with CereCore and are working well with them, so we really aren't looking at changing at this point. We brought CereCore in, really liked their product, really liked their model, and liked the way that they were planning on doing things, and there was a really good price point for us. We have been pleased ever since." 5/5 stars | Director, Dec 2025

“Feedback from clients about our partnership, as shared with KLAS or in our regular dealings with one another, inspires us and helps us identify opportunities to continually improve how we serve as managed IT services partners with some of healthcare’s top organizations,” said Watkins.

For more information on CereCore’s KLAS ranking, view the complete 2026 Best in KLAS Awards – Software and Services report.

About KLAS
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.]]>